The leading end-to-end industry-focused mRNA forum in Europe is back, advancing the next generation of mRNA medications toward clinical success.
Date: 28th – 30th January, 2025
Location: Frankfurt, Germany
This conference will feature the newest mRNA vaccination technologies for CMV, influenza, and TB in development, gene editing tools for rare diseases, novel engineering for RNA cell therapies, and new UK trials created for tailored mRNA cancer immunotherapies.As companies like Moderna, CureVac, Ethris, Afrigen Bio, sml Biopharm, and others share their ideas and assist guide your pipelines towards the next best approval, 2025 will bring new pre-clinical concepts and clinical trial progress updates.
Not only that, but two in-depth content tracks on Discovery & Pre-Clinical Development and Clinical Development & Manufacturing have been also added. These tracks will help you bring your design development reality and will provide you with clear guidance on how to overcome the most difficult delivery and safety bottlenecks. They will also give you the chance to establish new collaborations with cutting-edge biotechs, pharmaceutical companies, and academic institutions in the mRNA field.
A glimpse of the world-class speakers taking the stage is as follows:
Bo Ying, Chief Executive Officer, Abogen Biosciences
Shirley Hopper, Deputy Director National Licensing Strategy, MHRA
Marie Caby-Tosi, European Economic Area/ UK Qualified Person for Pharmacovigilance, Moderna
Alexander Zehnder, Chief Executive Officer, CureVac
Andreas Kuhn Senior Vice President – RNA Biochemistry & CMC, BioNTech SE
Zach Zhu, Chief Technology Officer, Innorna
Vincent Serra, Chief Scientific & Operating Officer, Neovacs
Pierre Wils, Global Scientific Advisory Lead, mRNA Centre of Excellence, Sanofi